Health Care [ 12/12 ] | Biotechnology [ 64/74 ]
NASDAQ | Common Stock
MyMD Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company.
It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms.
Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines.
The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases.
The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy.
The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs.
The company was founded in 2014 and is headquartered in Baltimore, Maryland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 13, 24 | -5.14 Decreased by -12.13 K% | - |
| Mar 29, 24 | -2.94 Decreased by -2.99 K% | - |
| Nov 14, 23 | 0.06 Increased by +171.33% | - |
| Aug 14, 23 | -0.11 Decreased by -25.00% | - |
| May 15, 23 | -0.04 Increased by +99.96% | - |
| Mar 31, 23 | -0.09 Increased by +99.91% | - |
| Nov 10, 22 | -0.09 Increased by +99.91% | - |
| Aug 15, 22 | -0.09 Increased by +99.91% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 0.00 Decreased by N/A% | -9.57 M Decreased by -129.52% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -9.80 M Decreased by -2.16 K% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -2.36 M Increased by +35.83% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | 4.04 M Increased by +210.40% | Increased by +N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -4.17 M Decreased by -14.62% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -433.14 K Increased by +89.49% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -3.68 M Decreased by -13.68% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -3.66 M Increased by +33.02% | Decreased by N/A% Decreased by N/A% |